brentuximab vedotin
seagen,takeda
['echelon']
6 year f/u echelon study shows overall survival advantage of a+avd vs abvd #eha22 via 
Haematology and Haemopoietic Stem Cell Transplantation , tweets and retweets for educational purposes only